How we manage smoldering multiple myeloma
Smoldering myeloma (SMM) is an asymptomatic stage characterized by bone marrow plasma cells infiltration between 10-60% in absence of myeloma-defining events and organ damage. Until the revision of criteria of MM to require treatment, two main prognostic models, not overlapping each other, were prop...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Hematology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8951 |
| _version_ | 1797936719670018048 |
|---|---|
| author | Alessandra Romano Claudio Cerchione Concetta Conticello Giovanni Martinelli Francesco Di Raimondo |
| author_facet | Alessandra Romano Claudio Cerchione Concetta Conticello Giovanni Martinelli Francesco Di Raimondo |
| author_sort | Alessandra Romano |
| collection | DOAJ |
| description | Smoldering myeloma (SMM) is an asymptomatic stage characterized by bone marrow plasma cells infiltration between 10-60% in absence of myeloma-defining events and organ damage. Until the revision of criteria of MM to require treatment, two main prognostic models, not overlapping each other, were proposed and used differently in Europe and in US. Novel manageable drugs, like lenalidomide and monoclonal antibodies, with high efficacy and limited toxicity, improvement in imaging and prognostication, challenge physicians to offer early treatment to high-risk SMM. Taking advantage from the debates offered by SOHO Italy, in this review we will update the evidence and consequent clinical practices in US and Europe to offer readers a uniform view of clinical approach at diagnosis, follow-up and supportive care in the SMM setting. |
| first_indexed | 2024-04-10T18:34:47Z |
| format | Article |
| id | doaj.art-f2b4929e0dd144e783244c220d3b49e7 |
| institution | Directory Open Access Journal |
| issn | 2038-8322 2038-8330 |
| language | English |
| last_indexed | 2024-04-10T18:34:47Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hematology Reports |
| spelling | doaj.art-f2b4929e0dd144e783244c220d3b49e72023-02-02T02:19:58ZengMDPI AGHematology Reports2038-83222038-83302020-09-0112s110.4081/hr.2020.8951How we manage smoldering multiple myelomaAlessandra Romano0Claudio Cerchione1Concetta Conticello2Giovanni Martinelli3Francesco Di Raimondo4Dipartimento di Chirurgia e Specialità Medico-Chirurgiche, Sezione di Ematologia, Università degli Studi di CataniaHematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, MeldolaU.O.C. di Ematologia, Azienda Policlinico Rodolico San Marco, CataniaHematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, MeldolaDipartimento di Chirurgia e Specialità Medico-Chirurgiche, Sezione di Ematologia, Università degli Studi di Catania; U.O.C. di Ematologia, Azienda Policlinico Rodolico San Marco, CataniaSmoldering myeloma (SMM) is an asymptomatic stage characterized by bone marrow plasma cells infiltration between 10-60% in absence of myeloma-defining events and organ damage. Until the revision of criteria of MM to require treatment, two main prognostic models, not overlapping each other, were proposed and used differently in Europe and in US. Novel manageable drugs, like lenalidomide and monoclonal antibodies, with high efficacy and limited toxicity, improvement in imaging and prognostication, challenge physicians to offer early treatment to high-risk SMM. Taking advantage from the debates offered by SOHO Italy, in this review we will update the evidence and consequent clinical practices in US and Europe to offer readers a uniform view of clinical approach at diagnosis, follow-up and supportive care in the SMM setting.https://www.pagepress.org/journals/index.php/hr/article/view/8951Smoldering multiple myeloma |
| spellingShingle | Alessandra Romano Claudio Cerchione Concetta Conticello Giovanni Martinelli Francesco Di Raimondo How we manage smoldering multiple myeloma Hematology Reports Smoldering multiple myeloma |
| title | How we manage smoldering multiple myeloma |
| title_full | How we manage smoldering multiple myeloma |
| title_fullStr | How we manage smoldering multiple myeloma |
| title_full_unstemmed | How we manage smoldering multiple myeloma |
| title_short | How we manage smoldering multiple myeloma |
| title_sort | how we manage smoldering multiple myeloma |
| topic | Smoldering multiple myeloma |
| url | https://www.pagepress.org/journals/index.php/hr/article/view/8951 |
| work_keys_str_mv | AT alessandraromano howwemanagesmolderingmultiplemyeloma AT claudiocerchione howwemanagesmolderingmultiplemyeloma AT concettaconticello howwemanagesmolderingmultiplemyeloma AT giovannimartinelli howwemanagesmolderingmultiplemyeloma AT francescodiraimondo howwemanagesmolderingmultiplemyeloma |